Endocannabinoid System

The endocannabinoid system is a foundational mammalian regulatory network — distinct from but in continuous dialogue with the nervous, endocrine, and immune systems — that modulates an unusually broad range of physiological functions. Its discovery is comparatively recent: the first receptor was characterized in 1988, the first endogenous ligand in 1992. The substantial subsequent research has revealed a regulatory system whose scope and physiological importance approach those of the better-known classical neurotransmitter systems.

The components

The system has four principal components:

1. Cannabinoid receptors.

• CB1. Concentrated in the central and peripheral [[nervous-system|nervous system]] — particularly dense in basal ganglia, cerebellum, hippocampus, cortex. Also present in adipose tissue, liver, reproductive organs. Activation typically reduces neurotransmitter release at the synapse where the receptor is located. CB1 is the most abundant G-protein-coupled receptor in the brain.
• CB2. Concentrated in immune tissues — spleen, tonsils, thymus, blood cells. Also present in some neural tissue (especially during inflammation) and various peripheral organs. Activation modulates immune function principally toward reduced inflammation.
• Other targets. Cannabinoids and endocannabinoids also interact with TRPV1, GPR55, GPR119, PPAR receptors, and serotonin (5-HT) receptors. The full pharmacology is substantially broader than CB1/CB2 alone.

2. Endogenous ligands (endocannabinoids).

The body produces its own cannabinoid-receptor ligands:

• Anandamide (N-arachidonoylethanolamine, AEA). Identified 1992 by Mechoulam and colleagues. The name derives from Sanskrit ananda (bliss). A partial agonist at CB1.
• 2-Arachidonoylglycerol (2-AG). Identified 1995. Substantially more abundant than anandamide; a full agonist at both CB1 and CB2. The principal endocannabinoid in most tissues.
• Other endocannabinoid-like compounds. N-arachidonoyldopamine (NADA), virodhamine, 2-arachidonoyl glyceryl ether (noladin ether), and others. The full endocannabinoidome is broader than the principal two ligands.

3. Synthesizing enzymes. The endocannabinoids are synthesized on demand from membrane phospholipid precursors by enzymes including N-acyl phosphatidylethanolamine phospholipase D (NAPE-PLD, for anandamide) and diacylglycerol lipase (DAGL, for 2-AG). Unlike classical neurotransmitters, endocannabinoids are not stored in vesicles — they are made when needed and released immediately.

4. Degrading enzymes. Endocannabinoids are degraded rapidly:

• FAAH (fatty acid amide hydrolase) — degrades anandamide.
• MAGL (monoacylglycerol lipase) — degrades 2-AG.

The rapid synthesis-and-degradation cycle is what gives the system its precise temporal control.

How the system works

The endocannabinoid system functions principally as a retrograde regulator — a substantially distinctive mode of operation in mammalian neurobiology.

The standard chemical-synapse picture: a presynaptic neuron releases a neurotransmitter; the neurotransmitter binds receptors on the postsynaptic neuron; the postsynaptic neuron responds. The endocannabinoid retrograde mechanism reverses the direction: the postsynaptic neuron, in response to its own activation, synthesizes and releases endocannabinoids that travel backward across the synapse to bind CB1 receptors on the presynaptic terminal, where they reduce subsequent neurotransmitter release.

The functional consequence: the postsynaptic neuron can dial down its own incoming signal. The system is a homeostatic feedback regulator — when activation is excessive, endocannabinoid release reduces it. This explains the broad regulatory scope: the system modulates virtually every neurotransmitter system because it acts as a universal feedback dampener.

What the system does

A non-exhaustive map of physiological functions:

• Pain processing. Endocannabinoid tone modulates nociceptive (pain) signaling at multiple levels — peripheral nerves, spinal cord, brain. CB1 activation reduces pain signaling; this is the principal mechanism behind cannabinoid analgesia.
• Mood and anxiety. Endocannabinoid signaling in limbic structures modulates mood and stress response. Reduced endocannabinoid tone is associated with depression and anxiety in animal models and increasingly in human studies.
• Appetite and metabolism. CB1 activation in hypothalamus and reward circuitry stimulates appetite (the munchies effect of THC); CB1 in adipose tissue and liver affects fat storage and lipid metabolism.
• Sleep. Endocannabinoid tone modulates sleep architecture, particularly REM sleep.
• Memory and learning. CB1 in hippocampus modulates memory consolidation; this is the mechanism behind THC’s short-term memory effects.
• Immune regulation. CB2 activation reduces inflammatory cytokine release; the endocannabinoid system is one of the principal regulators of immune homeostasis.
• Reproductive function. Endocannabinoids regulate fertility, embryo implantation, fetal development.
• Neurodevelopment. The system is particularly active during fetal and adolescent neural development; this is part of why adolescent THC exposure is concerning.
• Stress response. Acute stress increases endocannabinoid synthesis; chronic stress can dysregulate the system.

Clinical implications

Several therapeutic directions:

• Direct cannabinoid medicines. THC, CBD, and related compounds activate or modulate the system; their established therapeutic uses (epilepsy, pain, nausea, spasticity) work through this system.
• FAAH and MAGL inhibitors. Drugs that block the degradation enzymes elevate endogenous endocannabinoid tone; substantial pharmaceutical development in this area, with mixed clinical results so far.
• Endocannabinoid deficiency hypothesis. A working hypothesis that conditions like fibromyalgia, migraine, and irritable bowel syndrome may involve underactive endocannabinoid signaling. Suggestive evidence; not established clinical consensus.

Honest framing

The endocannabinoid system is comparatively recently discovered (post-1988) and substantially incompletely mapped. [[0mn1one|The platform]]‘s posture: take the established pharmacology seriously; recognize that the broader physiological role is still being clarified; resist both the hype that treats the endocannabinoid system as the master regulator of everything and the dismissal that treats cannabinoid medicine as marginal.

See also

Auto-generated from this entry’s typed relations: frontmatter, grouped by relation type so the editorial signal isn’t flattened.

• Parallels: [[cannabinoids]]
• Member of: [[body-system]]

Sources

1. Roger Pertwee (ed.). Handbook of [[cannabis|Cannabis]]. Oxford, 2014. Source class: handbook / definitive contemporary scholarly reference.
2. Vincenzo Di Marzo. Endocannabinoids: Actions at Non-CB1/CB2 Cannabinoid Receptors. Springer, 2015. Source class: scholarly survey.
3. Raphael Mechoulam et al. — foundational publications on endocannabinoid discovery, 1988–present. Source class: scholarly literature.
4. National Academies of Sciences. The Health Effects of [[cannabis|Cannabis]] and Cannabinoids. National Academies Press, 2017. Source class: scholarly survey.

Lenses still to grow

• Anandamide as separate compound entry.
• 2-AG as separate compound entry.
• CB1 receptor in detail.
• CB2 receptor in detail.
• The endocannabinoid deficiency hypothesis as continuing question.
• Neurodevelopmental implications of cannabinoid exposure.